Compare BLIN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLIN | BIVI |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 12.7M |
| IPO Year | 2018 | 2013 |
| Metric | BLIN | BIVI |
|---|---|---|
| Price | $0.75 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.26 |
| AVG Volume (30 Days) | 52.3K | ★ 224.1K |
| Earning Date | 08-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.83 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,568,000.00 | N/A |
| Revenue This Year | $20.26 | N/A |
| Revenue Next Year | $21.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $0.82 |
| 52 Week High | $1.42 | $3.79 |
| Indicator | BLIN | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 30.35 | 31.69 |
| Support Level | $0.70 | $1.10 |
| Resistance Level | $1.05 | $1.32 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 7.33 | 9.18 |
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.